Skip to content

Public FDA record

Z-0689-2008: Medtronic brand AneuRx AAAdvantage Endovascular Stent Graft with the Xcelerant Delivery System; Model

Recall record Z-0689-2008 for Medtronic CardioVascular. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-0689-2008
Company in FDA record
Medtronic CardioVascular
FDA classification date
Apr 8, 2008
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 20, 2026
Recall classification
Unknown — no matched enforcement classification

Reason stated in the source

Sterility compromised: Device sterility may be compromised as evidenced by a loss of outer package integrity.

Source facts

Action
Medtronic sent Urgent Communication - Medical Device Correction Advisory Notice letters to all its direct consignees on 12/7/07, via Federal Express, informing them of the affected product and providing instructions on avoiding contamination of the sterile surgical field with these devices.
Initiated
2007-12-10
Root cause
Package design/selection
Terminated
2008-07-28
Distribution
Nationwide Distribution.
Recall number
Z-0689-2008
Recall status
Terminated
CDRH record ID
67275
FDA classified
2008-04-08
Recall event number
46353

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗